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Asymptomatic hyperlipemia occurs in a significant number of American children. It is important to
recognize the condition during childhood because of
its role as a risk factor in the early onset of coronary
artery disease and because early dietary modification
may prevent changes leading to premature heart disease.
A predisposition to heart attack exists within
families, and now there is significant documentation
of familial aggregations of coronary atherosclerosis
as a concomitant of genetically determined risk factors such as hyperlipemia, hypertension, and diabetes
mellitus. 1 - 3 Of these three conditions, hyperlipemia,
which often displays a clearly genetic component, is
related most directly to the pathogenesis of atherosclerosis.
The following review will present the characteristics of juvenile hyperlipemia, note the known genetic influences, document its prevalence in children
in the United States, and present recommendations
for diagnosis and management.
Hyperlipemia is the manifestation of a variety of
biochemical abnormalities producing hypercholesterolemia and/or hypertriglyceridemia, both of which
are associated with an increased risk of coronary
artery disease in adults. Because hyperlipemia occurs
in early childhood and may lead to coronary atherosclerosis, the identification and treatment of children
with hyperlipemia should receive more attention than
it does at present. The definition of hyperlipemia is
indistinct; normal blood levels of cholesterol and triglycerides are defined statistically by measurements
in apparently healthy children. Although the levels
can vary geographically and may be influenced by
diet and other factors, "normal limits" have generally
been based on 90th percentile fiducial limits calcuCorrespondence and reprint requests to Dr. William W.
Miller, Box 291, Medical College of Virginia, Richmond, Virginia
23298.
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lated from relatively small samples (Table I ).4 A diagnosis of hyperlipemia is justified if lipid or lipoprotein concentrations, measured after a 12-hour fast,
are above these "riormal limits" on three separate
occasions at least two weeks apart. Both cholesterol
and triglyceride serum concentrations increase gradually throughout childhood and adolescence. Although the studies are limited, the normal range of
cholesterol levels appears to be relatively narrow except during the first year of life when serum cholesterol is especially affected by the type of fat in the
diet; consequently, unless the parents are hyperlipemic, diagnostic and therapeutic decisions are best
delayed until after six months or one year of age,
when a more mixed source of dietary fat is usual and
there is a diminished variation of serum lipid concentrations. The changes in serum triglyceride concentrations during childhood are less well defined than
are those for cholesterol, although a gradual increase
is commonly observed. In children with persistent
hyperlipemia, serum lipoprotein should be estimated
by electrophoresis, and a survey of other family members is indicated. These additiona l studies can greatly
facilitate a precise diagnosis when it is possible to
demonstrate similar findings in a parent or sibling.
The most widely used classification of hyperlipemic diseases is based upon the serum lipoprotein
pattern since blood lipids are bound to lipoproteins.
The term "hyperlipoproteinemia" is therefore often
preferred over " hyperlipemia" or " hyperlipidemia."
Six types of primary hyperlipoproteinemia are seen in
adults; all except type III have been detected in childhood or adolescence. A useful classification of juvenile hyperlipoproteinemia is illustrated in the Figure.
Hyperlipoproteinemia I, also known as familial
hyperchylomicronemia or lipoprotein lipase deficiency, is a rare autosoma l recessive trait. The biochemical defect is a deficiency of the enzyme, lipoprotein lipase. In homozygous children the disease is
usually characterized by elevated cholesterol and triMC V QUARTERLY 13(4): 160-1 64, 1977
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TABLE 1
Upper Limits of " Normal" of Plasma Lipid and Lipoprotein Cholesterol Concentrations (mg/ 100 ml ) in Infants, Children and Adolescents
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accidentally by a finding of milky plasma, hepatosplenomegaly, or lipemia retinalis. Premature atherosclerosis has not been documented in these patients;
however, the other symptoms and debilitating nature
of the disease make treatment mandatory.
Hyperlipoproteinemia II, also know as familial
hypercholesterolemia or familial hyperbetalipoproLIPIDS
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glyceride levels, a deficiency of lipoprotein lipase activity in post-heparin plasma or adipose tissue, chylomicron uptake in the skin a nd reticuloendothelial
tissue, abdo min al pain, and pancreatitis which may
be fatal. In children with xanthoma or pain the diagnosis is clinically obvious. However, in many children
who are asymptomatic the diagnosis may be made
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Figure-Phenotypic classification o f hyperlipoproteinem ias.
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teinemia, is inherited as an autosomal dominant trait.
It is the most common form of juvenile hyperlipemia
a nd is associated with a high risk of premature coronary artery disease. Hyperlipoproteinemia II accounts for many adults with myocardial infarction.
Biochemical abnormalities are now believed to be the
result of an absence or deficiency of a low-density
lipoprotein receptor on cell membranes. 5·6
The relatively common heterozygous form, hyperlipoproteinemia II A, has an estimated prevalence
of four per thousand 7; in a Seattle study approximately one out of every twenty adult survivors of
myocardial infarction was found to have this condition8; in a similar study 38 of 64 survivors had abnormal lipoprotein patterns. 9 These hyperlipemic fathers, all under 41 years of age, had 85 children of
whom 30 also had hyperlipoproteinemia II. Heterozygous infants have plasma cholesterol levels that are
two to three times normal by the end of the first year
of life. In matings between a heterozygous and a
normal parent, the affected children can be identified
at birth by cord-blood elevations of low-density lipoprotein cholesterol to values greater than 41 mg/ JOO
ml. 10 Tendinous xanthoma, corneal arcus, and coronary artery disease develop in young adults, usually
from 20 to 30 years of age. In about I 0% of children
with type II disease, there are mildly elevated levels of
very low-density lipoproteins and triglycerides along
with elevations in low-density lipoprotein cholesterol.11 This less common variation is classified as
familial hyperlipoproteinemia II B. 12
Homozygous children, who inherit a double
dose of the mutant gene, are much more severely
affected; the disease is often suspected initially because of the strong family history of heart disease.
Cholesterol levels, which may range from 500 to 1000
mg/ JOO ml, are frequently markedly elevated even at
birth, and corneal arcus and xanthoma appear before
adolescence. Coronary artery disease is clinically apparent before the age of 20 and survival beyond 30 is
rare.
In every family with a member who h as experienced a heart attack before the age of 50, serum
cholesterol and triglyceride levels should be measured
in all first-degree relatives. Those with normal lipid
values can be reassured about lipid risk factors and a
significant number of those with hyperlipemia can be
identified and treated early.
Hyperlipoproteinemia III , also known as "broad
Beta disease," "floating Beta disease," or dysbetalipoproteinemia, has not been detected in children,

MILLER: JUVENILE HYPERLIPEMIA
as noted previously. Inheritance is probably either
an autosomal recessive or an autosomal dominant
with incomplete penetrance.13 The condition results
in elevated levels of cholesterol and triglycerides with
an abnormal cholesterol to triglyceride ratio in the
very low-density lipoprotein . 14
Hyperlipoproteinemia IV, is relatively rare in
children and is also referred to as familial hypertriglyceridemia or endogenous hypertriglyceridemia.
Triglyceride levels are always elevated, ranging from
150 to 1000 mg/ 100 ml, and in about 20% of patients
the very low-density lipoprotein levels may result in a
hypercholesterolemia, with levels up to 350 mg/ 100
ml. 15 Clinical findings commonly include non-ketotic
diabetes and, less commonly, subcutaneous xanthoma . Obesity and hyperuricemia are frequent. A
significant proportion of adults under the age of 50
with angina or myocardial infarction have primary
type IV disease. 15 The condition appears to be heterogeneous. The biochemical a bnormality is not known,
but studies suggest a defect in very low-density lipoproteinemia catabolism. 16·17 It may occur in relatives
of patients with type III or type V lipoprotein abnormalities13 and in some families genetic transmission
follows an autosomal dominant pattern with delayed
expression.
Hyperlipoproteinemia V is rare in childhood.
Triglyceride levels range from 500 to 6,500 mg/ 100
ml and cholesterol varies from 150 to 1,500 mg/ 100
ml. Clinical findings are similar to those with type I
disease. Type V disease does not lead to premature
atherosclerosis; it is frequently associated with obesity, hyperuricemia, a nd abnormal glucose tolerance.
The inheritance of the primary disease is not known;
a family history of diabetes is common and there is a
high prevalence of type IV disease in first-degree relatives.
Many chronic childhood diseases are associated
with secondary hyperlipemia (Figure). Although infants with hypothyroidism usually have normal lipids
and lipoproteins, in older children hypothyroidism is
often associated with hypercholesterolemia which
can be reduced by adequate thyroid treatment. Most
children with the nephrotic syndrome have hypercholesterolemia, with close inverse correlations between cholesterol and albumin levels. In children
treated by renal dialysis, the practice of feeding high
fat diets to provide sufficient calories for growth may
result in secondary hyperlipoproteinemia and acceleration of atherosclerosis. Children with hepatic glycogenosis III have hyperlipoproteinemia, usually
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with increases in very low-density lipoproteins. Since
many of these children survive to adulthood, early
modification of the hyperlipemia by diet is indicated.
Children with obstructive liver disease often have
hyperlipemia unless the disease is at an advanced
stage. Diet a nd drug ma nagement of the hyperlipemia result in diminution in the symptoms and
lesions of xanthomatosis. In adolescents and young
adults other rare causes of hyperlipemia are pregnancy, alcoholism, adrenal disease, and the chronic
administration of adrenal corticosteroid drugs.
Dietary restriction and selection of fats is indicated in all children with primary hyperlipemias
(Table 2). Because skin xanthoma are diminished or
eliminated in children undergoing treatment, it is reasonable to conjecture that regression of vascular lipid
deposits, with a concomitantly decreased risk of corona ry artery disease, also occurs. In type I disease a
low-fat diet normalizes serum lipids and reduces or
prevents abdominal pain and pancreatitis. In type II
disease a low-fat, low-cholesterol diet with a high
ratio of polyunsaturated to saturated fats normalizes
lipids in type II A patients, reduces lipid levels significantly in type II B children, and diminishes xanthoma
in both. In type IV children a low-calorie, weightreduction diet is sufficient to normalize serum lipid.
In children with type V disease a low fat, moderate
cholesterol diet normalizes serum lipids and prevents
abdominal pain.

A low-cholesterol diet, 100 to 150 mg/ 100 ml, is
achieved by eliminating egg yolk, organ and fatty
meats, and shellfish, substituting skim milk and lowcholesterol margarine for whole milk and butter, using only cottage cheese among the cheeses and prohibiting products with coconut oil in them. 18
Diet management alone is inadequate in 85% of
type II children, and it is often necessary to u·se
cholestyramine, a nonabsorbable anionic resin and
bile acid sequestrant, which produces a n exchange of
chloride ions for bile acids in the intestine. The acids
are excreted in the feces, and the reduction in enzyme
product inhibition increases the endogenous metabolism of cholesterol, resulting in diminished serum
levels of very low-density and low-density lipoprotein
cholesterol. In doses of 250 to 800 mg/ kg/ day, cholestyramine does not cause malabsorption, although
constipation, epigastric discomfort, and bloating are
common. Beca use the drug absorbs fat, it can also
produce mild steatorrhea and poor absorption of fat
soluble vitamins. Its disagreeable taste is masked by
using fruit juice or incorporating it into cookies. The
surgical treatment of children with type II disease by
partial ilea! bypass is not recommended at this time.
In homozygous type II B children, the prognosis
for effective reduction in serum lipids is poor. Lowfat diets a nd la rge doses of cholestyramine, together
with the administration of nicotinic acid may be effective.19 Nicotinic acid, however, is often poorly tol-

TABLE 2
Treatment of Primary Juvenile Hyperlipemia
TYPE

DIET

DRUG

Low fat (10-15 g/ day)
Medium chain triglyceride
II A HETEROZYGOTE

II B HOMOZYGOTE

Low cholestero l ( 100-150 mg/day)
High polyunsaturated/
saturated ratio (2/ I)
Low cholesterol (100-150 mg/ day)
High polyunsatu rated/
saturated ratio (2/ 1)

EFFECT

Norm alizes lipids
Prevents pain and pancreatitis
Cholestyramine
(250- 800 mg/kg/ day)

Normal izes lipids. Reduction of
cardiovascular risk possible

Cho lestyram ine
500-1500 mg/ kg/ day
Nicotinic acid
25-75 mg/ kg/ day

Lowers lipids, Xanthoma diminish.
Reduction of cardiovascular
risk possible

IV

Low calorie weight control

Norma lizes lipids. Red uction in
cardiovascu lar risk possible

v

Low fat (20-30 g/ day)
Moderate cholesterol
(300-400 mg/ kg/ day)
Medi um chain triglyceride

Normalizes lipids prevents pain
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erated because of such side-effects as flushing, gastrointestinal distress, temporary hyperuricemia, glucose
intolerance, or hepatic dysfunction.
Nationwide reductions in dietary fat and cholesterol intake have been promulgated by various health
organizations. Most advisors recommend a reduction
of individual fat intake from 40% to 30% of the total
calories and a decrease in cholesterol and saturated
fats.
Juvenile hyperlipemia is relatively common in
the United States, and most affected children are
asymptomatic. Measurements of serum cholesterol
and triglycerides are indicated in all infants and children in families with one or more members having a
heart attack before the age of 50, because a significant proportion of these children will have hyperlipemia and will require dietary restrictions, and
some will need drug treatment. Early recognition and
management of juvenile hyperlipemia may diminish
the incidence or severity of coronary artery disease
decades later.
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